Two M&A deals and $9B later, Lonnie Moulder is ramping up his latest biotech startup. And this one comes with global vision built in.

3/23/21 Lonnie Moulder may have been in silent running mode in the 2 years since he closed the $5 billion sale of TESARO to GlaxoSmithKline. But he hasn’t been idle.

Today during the China Healthcare Investment Conference in Shanghai, Moulder’s taking the wraps off a biotech startup he’s put together that has assembled a pipeline with 7 drugs in it, a plan to add several more therapies and a quick vault into the clinic for a company with a small but fast-expanding team that is growing roots in China and the US.

Read More >